Kamel Khalili, Excision BioTherapeutics

FDA clears first-of-its-kind tri­al to see if CRISPR gene edit­ing can cure HIV

The FDA has cleared a com­pa­ny try­ing to use CRISPR gene-edit­ing to cure HIV to be­gin clin­i­cal tri­als.

The study, run by the start­up Ex­ci­sion Bio­Ther­a­peu­tics, will like­ly be­gin ear­ly next year, CMO Lisa Danzig said, af­ter fi­nal de­tails are hashed out. It will in­volve three groups of three healthy HIV pa­tients, with each group giv­en a se­quen­tial­ly high­er dose as the com­pa­ny tests the safe­ty of the new ther­a­py.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.